Improving Drug Candidate Success Through Evaluating Specificity, Immunogenicity, Functionality & Manufacturability  

Available On Demand

The concept of Developability underpins all aspects of antibody discovery, lead selection and lead optimisation. Developability at Abzena is addressed in the context of Specificity & Functionality, Immunogenicity & Safety and Manufacturability with additional considerations for ADCs and other bioconjugates.


Why assess Developability?

  • Allows the identification of risk factors early in the development process
  • Provides scope to apply design alterations to fix/reduce liabilities, or to develop strategies to manage liabilities
  • Reduces the likelihood of major issues arising at a later, more costly, stage of development
  • Ensures the selection of the best drug candidate(s) for development


Abzena combines Developability and Rational Design through the application of a series of stage appropriate in silico, in vitro and ex vivo experiments which have been designed to characterize and select a lead drug candidate with the greatest chance of clinical success.

Presenter
Maire Gerrard
Custom Content Writer
Informa Pharma Intelligence
Presenter
Dr Mark Frigerio
VP of Design & Developability
Abzena
View Biography

Registration details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

Submit